Another Blow To Aduhelm As Biogen Withdraws EU Filing
Adds To US Commercial Failure
Executive Summary
Biogen has withdrawn its filing of the Alzheimer’s drug before the EMA could reject it for the second time, perhaps hoping it could return with better data.
You may also be interested in...
Lecanemab Filing Complicates Biogen's Hunt For New CEO
Lecanemab is now filed for accelerated approval with the US FDA, but the wait for a Phase III readout could impact the hunt for Biogen’s next CEO.
Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
Biogen’s Aduhelm Competitors Boosted By Final CMS Coverage Decision
The Center for Medicare and Medicaid Services’ final decision on Medicare coverage favors anti-amyloid antibodies approved for Alzheimer’s disease based on efficacy rather than biomarker data.